Alex Dale, Author at Labiotech.eu

About

A former journalist intern at Labiotech, Alex now works as a copywriter in healthcare advertising. When he’s not writing, he enjoys playing sports and long-distance cycling.

Articles by Alex Dale

News and Trends 2 Nov 2017

Swedish Biotech Team Steps Up in the Fight Against Type 2 Diabetes

Two Swedish biotechs, Betagenon and Baltic Bio, have announced promising preliminary Phase IIa results for their Type 2 Diabetes candidate. Betagenon develops therapies for chronic energy balance disorders and has received funding from the EU’s program for research and innovation, Horizon 2020. Privately funded Betagenon has partnered up with Baltic Bio to share the profits from a type […]

November 2, 2017 - 2 minutesmins - By Alex Dale

News and Trends 2 Nov 2017

German Biotech Pockets €18M in its Series A to Propel Autoimmune Disease Candidate Forward

Topas Therapeutics received an extra €4M from Boehringer Ingelheim Venture Fund to help its autoimmune disease candidates accelerated through trials. Hamburg-based Topas Therapeutics, a spin-off from Evotec, develops products for autoimmune diseases with high medical need. With the announcement of a €18M Series A, it hopes to take begin moving its candidates into the clinic. It had raised €14M thanks to investment from Epidarex […]

November 2, 2017 - 2 minutesmins - By Alex Dale

Interview 2 Nov 2017

Meet the Top Biotech Investor Who Picked His Career By Accident

Kevin Johnson, Partner at Medicxi, joined us last week for our Meetup in London. He told us how he ended as an investor despite starting in biotech. Fresh from his PhD at Cambridge, Johnson stepped into biotech and led the development of a number of human antibodies at Cambridge Antibody Technology (CAT). The company was eventually responsible for […]

November 2, 2017 - 4 minutesmins - By Alex Dale

News and Trends 1 Nov 2017

Belgian Biotech Launches IPO, Readying Itself to Fight Multiple Sclerosis

Apitope develops highly specific peptide therapeutics for multiple sclerosis and other autoimmune diseases, and will now launch an IPO on Brussels Euronext. Apitope hopes to treat a number of autoimmune diseases affecting many systems throughout the body. The company has developed peptides, ‘apitopes‘, that tackle the immunological basis of the disease. The company has just […]

November 1, 2017 - 2 minutesmins - By Alex Dale

News and Trends 30 Oct 2017

German Pharmacist Finds a Way to Put the Brakes on Gallbladder Cancer

Research has identified a protein that drives tumor growth, which opens up a new therapeutic target for gallbladder cancer. Gallbladder cancer is often detected too late to be treated effectively as it shows few symptoms. Research, published in Oncotarget, has identified a pathway that could help to improve prognosis and treatment of the disease. Sonja Kessler discovered […]

October 30, 2017 - 3 minutesmins - By Alex Dale

News and Trends 27 Oct 2017

French Biotech Gets Together with L’Oréal to Clean up our Streets

Carbios and L’Oréal have had enough of the plastics bags and packaging littering our streets and will form a consortium for the bio-recycling of plastic on an industrial scale. Today, you’ll struggle to walk along a street without seeing plastic bottles, bags, and wrappers dropped by the wayside… but thankfully, help is at hand. Carbios, […]

October 27, 2017 - 3 minutesmins - By Alex Dale

More News! 27 Oct 2017

Lack of Permanent Academic Roles is Frightening News for PhD Students

With Halloween around the corner, PhD students probably felt safe from any nasty surprises for a few more days but their careers in academia may have hit a snag. PhD students work very hard, but surely it is all worth it for the guarantee of a good job at the end of it all? A study […]

October 27, 2017 - 3 minutesmins - By Alex Dale

News and Trends 26 Oct 2017

New and Improved CRISPR: More Precise Genome Editing Now Possible

US Scientists have developed a new form of CRISPR, base editing, which can repair tiny genome segments, smaller than a single gene. Here at Labiotech, we focus on European biotech, but this was too big to miss: Researchers based at MIT and Harvard have described a new way of editing DNA and RNA — base […]

October 26, 2017 - 3 minutesmins - By Alex Dale

News and Trends 25 Oct 2017

Shire’s Hemophilia Gene Therapy Boosted by Orphan Drug Designation

The FDA has granted orphan drug designation to Shire’s hemophilia A gene therapy, giving it the boost it needs to catch up with others in the field. Shire specializes in the development of drugs for rare diseases, including hemophilia A – a bleeding disorder caused by a lack of clotting factor VIII activity in the […]

October 25, 2017 - 1 minutemin - By Alex Dale

nanoparticles cancer thermotherapy UK2 1

News and Trends 25 Oct 2017

British Researchers Develop Clever Nanoparticles to Kill Cancer Cells

The University of Surrey has developed nanoparticles that heat up to kill cancer cells, but can then be controlled to protect healthy tissue. Research from the University of Surrey, published in Nanoscale, has been put forward as a new form of thermotherapy. Although it has been available for a long time, thermotherapy’s use is limited by […]

October 25, 2017 - 3 minutesmins - By Alex Dale

Interview 25 Oct 2017

What Could RNA Therapies Do for the Treatment of CNS Disorders?

Evelyn chatted with Thomas de Vlaam to find out what his company, Amylon, is working on and how it hopes to change the field fighting CNS disorders. De Vlaam came up with AT-010, a drug candidate for the treatment of Katwijk‘s disease, during his time at ProQR. When it became clear that he had something […]

October 25, 2017 - 3 minutesmins - By Alex Dale

News and Trends 24 Oct 2017

Update: GSK’s Shingles Vaccines Impresses FDA Panel who Push for its Approval

Update (24/10/2017): Shingrix has been approved by the FDA and will cost $280 (€238) for the required two shots, which should be covered by most insurance plans. Originally published on 13/9/2017 An FDA panel voted 11-0 to support the approval of GSK’s new shingles vaccine based on “impressive” efficacy and safety results in a Phase III […]

October 24, 2017 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Alex Dale

About

Articles by Alex Dale

Swedish Biotech Team Steps Up in the Fight Against Type 2 Diabetes

German Biotech Pockets €18M in its Series A to Propel Autoimmune Disease Candidate Forward

Meet the Top Biotech Investor Who Picked His Career By Accident

Belgian Biotech Launches IPO, Readying Itself to Fight Multiple Sclerosis

German Pharmacist Finds a Way to Put the Brakes on Gallbladder Cancer

French Biotech Gets Together with L’Oréal to Clean up our Streets

Lack of Permanent Academic Roles is Frightening News for PhD Students

New and Improved CRISPR: More Precise Genome Editing Now Possible

Shire’s Hemophilia Gene Therapy Boosted by Orphan Drug Designation

British Researchers Develop Clever Nanoparticles to Kill Cancer Cells

What Could RNA Therapies Do for the Treatment of CNS Disorders?

Update: GSK’s Shingles Vaccines Impresses FDA Panel who Push for its Approval

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Alex Dale

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!